Frances E Jensen Selected Research

Tuberous Sclerosis (Bourneville's Disease)

4/2012	Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.
1/2012	The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.
11/2011	Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.
4/2008	Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers.
5/2007	A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frances E Jensen Research Topics

Disease

37	Seizures (Absence Seizure) 04/2024 - 06/2002
18	Hypoxia (Hypoxemia) 01/2023 - 06/2002
13	Epilepsy (Aura) 04/2024 - 04/2008
9	Periventricular Leukomalacia (Neonatal Cerebral Leukomalacia) 04/2015 - 04/2002
7	Brain Injuries (Brain Injury) 01/2017 - 06/2002
6	Ischemia 03/2016 - 06/2002
5	Tuberous Sclerosis (Bourneville's Disease) 04/2012 - 05/2007
3	Alzheimer Disease (Alzheimer's Disease) 08/2022 - 01/2020
2	CDKL5 deficiency disorder 04/2024 - 12/2019
2	Disease Progression 11/2023 - 07/2009
2	Temporal Lobe Epilepsy 01/2020 - 01/2018
2	Intellectual Disability (Idiocy) 12/2019 - 11/2011
2	Autism Spectrum Disorder 01/2018 - 03/2016
2	Status Epilepticus (Complex Partial Status Epilepticus) 08/2015 - 05/2014
2	Drug Resistant Epilepsy 05/2014 - 04/2012
2	Brain Hypoxia (Cerebral Hypoxia) 01/2013 - 04/2009
2	Autistic Disorder (Autism) 01/2012 - 11/2011
1	Prodromal Symptoms 04/2024
1	Neurodevelopmental Disorders 04/2024
1	Ataxia (Dyssynergia) 01/2023
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2023
1	Cognitive Dysfunction 01/2020
1	Amyloid Plaque 01/2020
1	Rare Diseases (Rare Disease) 12/2019
1	Rett Syndrome (Rett's Disorder) 01/2018
1	Brain Diseases (Brain Disorder) 03/2016
1	Congenital Heart Defects (Congenital Heart Defect) 10/2015
1	Hypothermia 06/2015
1	Nervous System Diseases (Neurological Disorders) 05/2014
1	Neoplasms (Cancer) 04/2014
1	Medulloblastoma 04/2014
1	Encephalitis (Encephalitis, Rasmussen) 02/2014

Drug/Important Bio-Agent (IBA)

12	Anticonvulsants (Antiepileptic Drugs)IBA 02/2016 - 06/2004
9	AMPA Receptors (AMPA Receptor)IBA 01/2024 - 05/2004
7	Glutamate Receptors (Glutamate Receptor)IBA 01/2015 - 06/2002
5	Bumetanide (Bumex)FDA LinkGeneric 01/2021 - 11/2005
5	2,3- dioxo- 6- nitro- 7- sulfamoylbenzo(f)quinoxaline (NBQX)IBA 01/2018 - 06/2004
5	TOR Serine-Threonine KinasesIBA 03/2016 - 04/2008
5	Kainic Acid (Kainate)IBA 05/2014 - 05/2004
4	gamma-Aminobutyric Acid (GABA)IBA 04/2024 - 03/2005
4	Sirolimus (Rapamycin)FDA Link 04/2024 - 11/2011
4	Mechanistic Target of Rapamycin Complex 1IBA 04/2024 - 01/2012
4	Biomarkers (Surrogate Marker)IBA 11/2023 - 07/2009
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2013
4	Glutamic Acid (Glutamate)FDA Link 05/2014 - 06/2002
4	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 05/2014 - 06/2002
4	trans-sodium crocetinate (crocetin)IBA 04/2012 - 05/2007
3	Pentylenetetrazole (Metrazol)IBA 04/2024 - 08/2015
3	Phenobarbital (Luminal)FDA Link 01/2021 - 04/2011
3	N-Methylaspartate (NMDA)IBA 01/2015 - 11/2011
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2024 - 12/2019
2	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2020 - 03/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2015 - 06/2015
2	Member 2 Solute Carrier Family 12IBA 04/2015 - 01/2013
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2014 - 06/2008
2	Levetiracetam (Keppra)FDA LinkGeneric 01/2013 - 11/2006
2	Glucose (Dextrose)FDA LinkGeneric 07/2009 - 05/2003
2	Oxygen (Dioxygen)IBA 07/2009 - 05/2003
2	Kainic Acid Receptors (Kainate Receptor)IBA 03/2005 - 05/2004
2	Topiramate (Topamax)FDA LinkGeneric 06/2004 - 05/2004
1	MTOR InhibitorsIBA 04/2024
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2024
1	CannabidiolIBA 04/2024
1	AcidsIBA 01/2024
1	perampanelIBA 01/2023
1	Therapeutic UsesIBA 01/2023
1	NAD (NADH)IBA 08/2022
1	Actin Depolymerizing Factors (Cofilins)IBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	AntibodiesIBA 01/2020
1	JNK Mitogen-Activated Protein KinasesIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	EnzymesIBA 01/2020
1	IEM 1460IBA 12/2019
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	Methyl-CpG-Binding Protein 2IBA 01/2018
1	CystathionineIBA 01/2017
1	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 01/2017
1	CalciumIBA 10/2016
1	Fragile X Mental Retardation ProteinIBA 03/2016
1	Lorazepam (Ativan)FDA LinkGeneric 08/2015
1	ChloridesIBA 04/2015
1	A-factor (Streptomyces)IBA 04/2015
1	lestaurtinibIBA 05/2014
1	Messenger RNA (mRNA)IBA 05/2014
1	Tyrosine Kinase InhibitorsIBA 05/2014
1	GABA Receptors (GABA Receptor)IBA 05/2014
1	Neurotransmitter Receptors (Neurotransmitter Receptor)IBA 04/2014
1	Small Interfering RNA (siRNA)IBA 04/2014
1	EpitopesIBA 02/2014
1	AutoantibodiesIBA 02/2014
1	Serine (L-Serine)FDA Link 12/2012
1	AMPA 1 glutamate receptor ionotropicIBA 12/2012

Therapy/Procedure

9	Therapeutics 01/2022 - 11/2006
1	Induced Hyperthermia (Thermotherapy) 01/2023
1	Transcranial Direct Current Stimulation 08/2015
1	Drug Therapy (Chemotherapy) 04/2014
1	Hemispherectomy 02/2014